Latest Period
Q2 2026
Security Snapshot
Kyverna Therapeutics, Inc. - Common Stock, $0.00001 par value per share (KYTX) Institutional Ownership
CUSIP: 501976104
13F Institutional Holders and Ownership History from Q1 2024 to Q2 2026
Institutions Reporting
120
Shares (Excl. Options)
37,594,332
Price
$8.91
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.00001 par value per share
- Symbol
- KYTX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 37,594,332
- Total 13F value
- $334,958,316
- Portfolio coverage rank
- 0%
- Share change
- +2,872,500
- Value change
- +$25,975,179
- Number of holders
- 120
- Shares outstanding
- 60,736,842
- SEC-reported price per share
- $7.29
- Insider filing price
- $7.29
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- KYTX - Kyverna Therapeutics, Inc. - Common Stock, $0.00001 par value per share is tracked under CUSIP 501976104.
- 120 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 111 to 120 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $300,524,364 to $334,958,316.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 120 institutions filings for Q2 2026.
Security key
501976104
Latest holder period
Q2 2026
13F holders
120
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
KYTX full holder history
Kyverna Therapeutics, Inc. SEC filings
Kyverna Therapeutics, Inc. company facts
Kyverna Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 501976104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
KYTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Westlake BioPartners Fund I, L.P. | 7.8% | $43,778,216 | 4,657,257 | Dr. Beth C. Seidenberg ("Seidenberg") | 31 Dec 2025 | |||
| Northpond Ventures III, LP | 6.1% | $28,531,978 | 3,466,826 | Michael P. Rubin | 31 Dec 2025 | |||
| BlackRock, Inc. | 5.1% | $27,654,475 | 3,103,757 | BlackRock, Inc. | 30 Jun 2026 | |||
| GordonMD Global Investments LP | 7% | $23,275,071 | 3,058,485 | GordonMD Global Investments LP | 13 Nov 2025 | |||
| Bain Capital Life Sciences Opportunities III, LP | 4.8% | -13% | $25,705,350 | -$2,004,750 | 2,885,000 | -7.2% | Bain Capital Life Sciences Opportunities III, LP | 30 Jun 2026 |
As of 30 Jun 2026, 120 institutional investors reported holding 37,594,332 shares of Kyverna Therapeutics, Inc. - Common Stock, $0.00001 par value per share (KYTX). This represents 62% of the company’s total 60,736,842 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
54%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GordonMD Global Investments LP | 7% | 4,244,818 | 0% | 23% | $37,821,328 |
| GILEAD SCIENCES, INC. | 6.8% | 4,126,119 | 0% | 2.2% | $36,763,720 |
| BlackRock, Inc. | 5.2% | 3,134,807 | +257% | 0% | $27,931,130 |
| Bain Capital Life Sciences Investors, LLC | 4.8% | 2,885,000 | -7.2% | 1.5% | $25,705,350 |
| AIGH Capital Management LLC | 4.6% | 2,795,797 | +40% | 2.3% | $24,910,552 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.3% | 2,000,000 | 0% | 0.19% | $17,820,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.1% | 1,897,451 | +6.4% | 0% | $16,906,288 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2% | 1,186,023 | -24% | 0% | $10,569,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 1,049,430 | +148% | 0% | $9,352,537 |
| Insight Holdings Group, LLC | 1.6% | 989,054 | 0% | 0.67% | $8,812,471 |
| MORGAN STANLEY | 1.6% | 982,307 | +0.51% | 0% | $8,752,355 |
| STATE STREET CORP | 1.6% | 982,233 | +610% | 0% | $8,751,696 |
| Propel Bio Management, LLC | 1.5% | 883,198 | +37% | 4.1% | $7,869,294 |
| Woodline Partners LP | 1.4% | 845,325 | 0% | 0.02% | $7,531,846 |
| MILLENNIUM MANAGEMENT LLC | 1.1% | 639,780 | -36% | 0% | $5,700,440 |
| MBB PUBLIC MARKETS I LLC | 1% | 614,477 | 0% | 0.59% | $5,474,990 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.82% | 500,000 | 0% | 0.01% | $4,455,000 |
| D. E. Shaw & Co., Inc. | 0.77% | 469,346 | -35% | 0% | $4,181,872 |
| WELLS FARGO & COMPANY/MN | 0.61% | 373,009 | +226% | 0% | $3,323,510 |
| UBS Group AG | 0.6% | 365,574 | -19% | 0% | $3,257,264 |
| GOLDMAN SACHS GROUP INC | 0.55% | 335,230 | +57% | 0% | $2,986,899 |
| RENAISSANCE TECHNOLOGIES LLC | 0.55% | 333,899 | -9.1% | 0% | $2,975,040 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.53% | 319,666 | +51% | 0% | $2,848,224 |
| NORTHERN TRUST CORP | 0.52% | 315,354 | +304% | 0% | $2,809,805 |
| BNP PARIBAS FINANCIAL MARKETS | 0.51% | 310,632 | 0% | 0% | $2,767,731 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Latest
Q2 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 37,594,332 | $334,958,316 | +$25,975,179 | $8.91 | 120 |
| 2026 Q1 | 34,823,469 | $300,524,364 | +$1,033,862 | $8.63 | 111 |
| 2025 Q4 | 34,131,760 | $320,775,226 | +$111,162,333 | $9.40 | 99 |
| 2025 Q3 | 22,688,863 | $136,134,153 | -$2,158,017 | $6.00 | 74 |
| 2025 Q2 | 23,200,134 | $71,227,727 | -$5,373,744 | $3.07 | 77 |
| 2025 Q1 | 25,800,890 | $49,797,231 | -$8,775,592 | $1.93 | 86 |
| 2024 Q4 | 28,863,400 | $107,952,189 | -$6,920,913 | $3.74 | 87 |
| 2024 Q3 | 28,136,737 | $138,294,516 | -$28,965,516 | $4.89 | 92 |
| 2024 Q2 | 31,935,411 | $239,516,646 | -$86,044,405 | $7.50 | 87 |
| 2024 Q1 | 30,688,965 | $762,283,849 | +$760,773,578 | $24.84 | 88 |